Camurus AB (publ) (CAMRF)
| Market Cap | 3.19B |
| Revenue (ttm) | 202.83M |
| Net Income (ttm) | 54.57M |
| Shares Out | n/a |
| EPS (ttm) | 0.91 |
| PE Ratio | 58.40 |
| Forward PE | 29.96 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 200 |
| Average Volume | 20 |
| Open | n/a |
| Previous Close | n/a |
| Day's Range | n/a |
| 52-Week Range | 46.15 - 66.69 |
| Beta | 0.58 |
| RSI | 24.58 |
| Earnings Date | Jul 17, 2025 |
About Camurus AB
Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain; and Brixadi to treat opioid use disorder. It also provides CAM2038 for the treatment of chronic pain; CAM2029, which completed phase III clinical trials for the treatment of acromegaly, and phase III clinical trials to treat gastroenteropancreatic neuroendocri... [Read more]
Financial Performance
In 2024, Camurus AB's revenue was 1.87 billion, an increase of 8.78% compared to the previous year's 1.72 billion. Earnings were 428.39 million, a decrease of -0.71%.
Financial numbers in SEK Financial StatementsNews
CHMP recommends approval of Oczyesa® for treatment of acromegaly in the EU
LUND, Sweden , April 25, 2025 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positi...
US FDA declines to approve Camurus' rare hormone disorder drug
The U.S. Food and Drug Administration has declined to approve Camurus' drug for the treatment of a rare hormonal disorder due to deficiencies at a third-party manufacturing facility, the Swedish drugm...
New publication shows effectiveness data for weekly and monthly buprenorphine injections in treating opioid dependence in individuals using fentanyl
LUND, Sweden , June 25, 2024 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced the publication in JAMA Network Open of a new post hoc analysis from a 24-week randomized, double-blind, Phase 3...